BAD and prostate cancer: The BAD protein represents a switch integrating the antiapoptotic effects of multiple pathways in prostate cancer cells, thus expression of a nonphosphorylatable mutant S112A-BAD reduces the survival effects of growth factors such as EGF in prostate cancer cells [27], [30].